

Special Issue

Immunotherapeutics for Treating Infectious Diseases and Beyond

Message from the Guest Editors

Immunotherapy or immune-based therapy has a long history of success in the treatment of a wide range of human diseases, including cancer and infectious, metabolic, and autoimmune diseases, serving as a promising substitute to chemotherapeutics. This strategy involves the use of biological and/or synthetic agents to modulate host immune responses toward the cure. New technological advancements have been made to enhance the effects of therapeutic antibodies by employing several modifications, such as antibody engineering (Fc engineering, glycoengineering), as well as developing human, humanized, chimeric, and bispecific antibodies, etc. Despite this, in recent years, functional limitations related to immunotherapeutics, including inadequate pharmacokinetics and compromised non-specific interactions within the immune system, have been revealed and these deficits indicate the need to perform additional in-depth research and more significant efforts in this direction.

Guest Editors

Dr. Sneha Ratnapriya

Dr. Keerti Rawat

Dr. Yonatan Butbul Aviel

Deadline for manuscript submissions

closed (31 January 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/137288

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).